tradingkey.logo

Sanofi SA

SNY

59.150USD

+1.450+2.51%
Close 03/05, 16:00ETQuotes delayed by 15 min
148.29BMarket Cap
24.50P/E TTM

Sanofi SA

59.150

+1.450+2.51%
More Details of Sanofi SA Company
Company Info
Company codeSNY
Company nameSanofi SA
IPO dateJul 01, 2002
Founded at1994
CEOMr. Paul Hudson, Ph.D.
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJul 01
Address46 Avenue de la Grande Armee
CityPARIS
Stock exchangeNASDAQ Global Select Consolidated
CountryFrance
Postal code75017
Phone33153774000
Websitehttps://www.sanofi.com/
Company codeSNY
IPO dateJul 01, 2002
Founded at1994
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Madeleine Roach
Ms. Madeleine Roach
Executive Vice President - Business Operations, Member of the Executive Committee
Executive Vice President - Business Operations, Member of the Executive Committee
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Mr. Roy Papatheodorou
Mr. Roy Papatheodorou
Executive Vice President, General Counsel, Member of the Executive Committee
Executive Vice President, General Counsel, Member of the Executive Committee
--
--
Mr. John Sundy
Mr. John Sundy
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Prof. Dr. Houman Ashrafian, M.D., Ph.D.
Prof. Dr. Houman Ashrafian, M.D., Ph.D.
Executive Vice President, Head of Research and Development, Member of the Executive Committee
Executive Vice President, Head of Research and Development, Member of the Executive Committee
--
--
Mr. Brian Foard
Mr. Brian Foard
Executive Vice President - Specialty Care, Member of the Executive Committee
Executive Vice President - Specialty Care, Member of the Executive Committee
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Madeleine Roach
Ms. Madeleine Roach
Executive Vice President - Business Operations, Member of the Executive Committee
Executive Vice President - Business Operations, Member of the Executive Committee
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Mr. Roy Papatheodorou
Mr. Roy Papatheodorou
Executive Vice President, General Counsel, Member of the Executive Committee
Executive Vice President, General Counsel, Member of the Executive Committee
--
--
Revenue Breakdown
Currency: USDUpdate time: Wed, Mar 5
Currency: USDUpdate time: Wed, Mar 5
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
7.56B
51.24%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
4.02B
27.28%
Europe
3.17B
21.47%
By Business
By Region
No Data
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
2.97%
Fisher Investments
0.49%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.42%
Barrow Hanley Global Investors
0.30%
Other
95.34%
Shareholder Statistics
Shareholder
Proportion
Dodge & Cox
2.97%
Fisher Investments
0.49%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.42%
Barrow Hanley Global Investors
0.30%
Other
95.34%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
5.58%
Investment Advisor
3.82%
Research Firm
0.78%
Hedge Fund
0.31%
Holding Company
0.11%
Bank and Trust
0.06%
Pension Fund
0.01%
Other
89.30%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1217
270.67M
10.71%
-28.12M
2024Q4
1263
270.43M
10.70%
-30.67M
2024Q3
1239
286.02M
11.43%
-5.71M
2024Q2
1248
275.46M
11.01%
-5.49M
2024Q1
1232
261.24M
10.33%
-7.61M
2023Q4
1213
251.24M
9.93%
-18.33M
2023Q3
1178
256.17M
10.15%
-15.97M
2023Q2
1173
257.64M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
2022Q4
1167
264.15M
10.47%
-6.08M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
75.22M
2.97%
-1.07M
-1.41%
Dec 31, 2024
Fisher Investments
12.51M
0.49%
-848.08K
-6.34%
Dec 31, 2024
Invesco Advisers, Inc.
11.37M
0.45%
+303.99K
+2.74%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.84M
0.42%
+5.08M
+88.49%
Dec 31, 2024
Barrow Hanley Global Investors
7.69M
0.3%
-140.54K
-1.79%
Dec 31, 2024
Managed Account Advisors LLC
7.30M
0.28%
-658.51K
-8.27%
Dec 31, 2024
Boston Partners
5.39M
0.21%
+2.50M
+86.37%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.94M
0.19%
-3.65M
-42.49%
Dec 31, 2024
Wellington Management Company, LLP
4.48M
0.17%
-166.01K
-3.56%
Dec 31, 2024
BofA Global Research (US)
4.27M
0.16%
+1.05M
+32.70%
Dec 31, 2024
View more
Related ETFs
Update time: 14 hours ago
Update time: 14 hours ago
Name
Proportion
VanEck Pharmaceutical ETF
4.75%
Pacer Trendpilot European Index ETF
4.05%
Invesco International Dividend Achievers ETF
3.43%
Putnam Focused Large Cap Value ETF
2.92%
Pacer Global Cash Cows Dividend ETF
2.15%
Brandes US Value ETF
2.11%
Altrius Global Dividend ETF
2.04%
ProShares Ultra Nasdaq Biotechnology
1.6%
Invesco Nasdaq Biotechnology ETF
1.52%
Simplify Health Care ETF
1.18%
View more
VanEck Pharmaceutical ETF
Proportion4.75%
Pacer Trendpilot European Index ETF
Proportion4.05%
Invesco International Dividend Achievers ETF
Proportion3.43%
Putnam Focused Large Cap Value ETF
Proportion2.92%
Pacer Global Cash Cows Dividend ETF
Proportion2.15%
Brandes US Value ETF
Proportion2.11%
Altrius Global Dividend ETF
Proportion2.04%
ProShares Ultra Nasdaq Biotechnology
Proportion1.6%
Invesco Nasdaq Biotechnology ETF
Proportion1.52%
Simplify Health Care ETF
Proportion1.18%
Dividend
A total of 23.51B USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.